Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2023-04-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于部分非公开发行股票募投项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Tian Kang Biological Co., Ltd. regarding the completion of a non-public stock issuance investment project and the permanent allocation of surplus raised funds to working capital. It details the use of funds raised from a non-public stock issuance, the completion status of the investment project, surplus funds, and the company's plan to use these surplus funds. It includes references to regulatory approvals, board and supervisory committee meetings, independent director opinions, and sponsor institution verification. The document is a formal disclosure about the use of raised capital and related corporate governance procedures, not a full financial report or earnings release. It is a regulatory announcement about capital use and project completion, fitting the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about capital use, not just a brief notice or report publication announcement. Therefore, the best classification is CAP with high confidence.
2023-04-28 Chinese
关于持股5%以上股东所持公司股份解除冻结的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the unfreezing of shares held by a shareholder owning more than 5% of the company's stock. It details the shareholder's name, the number of shares unfrozen, and related legal and risk information. There are no financial statements, earnings data, or management discussions. The content focuses on shareholding status changes and legal status of shares, which aligns with notifications about major shareholding changes or related shareholder information. The document length is short (1424 characters), and it is a formal announcement rather than a report or detailed filing. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ).
2023-04-17 Chinese
关于天康生物股份有限公司2023年第三次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2023 third extraordinary general meeting (EGM) of Tian Kang Biological Co., Ltd. It details the legality of the meeting's notice, attendance, voting procedures, and results. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the meeting's compliance with laws and company bylaws. It is related to a shareholders' meeting but is not the meeting materials or voting results announcement itself. Given the nature of the document as a legal opinion letter for a shareholders meeting, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories. The document length is short (2900 characters), and it is not an announcement of a report publication but a standalone legal opinion. Therefore, the classification is RNS with high confidence.
2023-04-12 Chinese
2023年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2023 third extraordinary general meeting of shareholders" of Tian Kang Biological Co., Ltd. It details the meeting date, voting methods, attendance, and the voting results on specific proposals. It also includes a legal opinion from a law firm confirming the legality of the meeting and resolutions. The document is an official announcement of the voting results from a shareholders' meeting, not the meeting materials or the full report itself. The length is about 2063 characters, which is relatively short and consistent with a voting results announcement. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-04-12 Chinese
关于与定西市人民政府签署战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a strategic cooperation framework agreement between the company (天康生物股份有限公司) and the local government (定西市人民政府). It details the investment plans, project scope, and cooperation terms but does not contain any financial statements or report data. The document is relatively short (3787 characters) and serves as a formal disclosure of a business cooperation agreement, not a financial report or earnings release. It is not a management change, capital update, or voting result announcement. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a strategic cooperation agreement without financial data or report content.
2023-04-12 Chinese
关于2023年3月份生猪销售简报
Regulatory Filings Classification · 95% confidence The document is a sales brief for March 2023 from Tian Kang Biological Co., Ltd., detailing sales volume and revenue of live pigs. It includes month-over-month and year-over-year comparisons, reasons for sales growth, and risk warnings. The document is short (894 characters) and does not contain comprehensive financial statements or detailed financial analysis. It is a periodic sales update rather than a full financial report or earnings release. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is an operational sales update, which is not explicitly covered by the other categories. Given the nature and length, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and disclosures that do not fit other categories.
2023-04-07 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.